Home

QVT Associates GP LLC

CIK 1290166 · last filed 2019-06-19

QVT Associates GP LLC is a corporate insider who has filed 46 SEC Form 4 insider transactions across 9 companies since 2009. The most recent filing shows the insider bought $302.8K of UROV on Jun 19, 2019. Across all open-market trades the lifetime net is +$50.7M, making them a net buyer over the disclosed history. The firm reports its address in New York, NY. 23 SEC filings were submitted jointly with QVT Fund V LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

9

Total Filings

46

Lifetime Open-Market Net

$50.72M

Filer Profile

Reported Address
1177 AVENUE OF THE AMERICAS
9TH FLOOR
NEW YORK, NY 10036
Phone
(212) 705-8800
State of Incorporation
DE
Related Filers
QVT Fund V LP — 23 joint filings, latest 2019-07-12
QVT Financial Investment Cayman Ltd. — 11 joint filings, latest 2019-07-12
AGENUS INC — 2 joint filings, latest 2015-01-13
QVT Offshore Ltd. — 1 joint filings, latest 2018-12-20
AHAC Sponsor III LLC — same reported address
Gates Capital Management GP, LLC — same reported address
Gates Capital Management, L.P. — same reported address
Metalmark Capital Partners II GP, L.P. — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Urovant Sciences Ltd. (UROV) Delisted 10%+ Owner 22,860,013 $16.24 $371.25M $76.13M 5 2019-06-19
Myovant Sciences Ltd. (MYOV) Delisted 10%+ Owner 40,765,599 $26.98 $1.10B $40.00M 1 2019-06-06
ABUS Director — $5.15 — $0 2 2018-01-16
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted 10%+ Owner 559,999 $8.37 $4.69M $8.40M 1 2014-02-21
ACHILLION PHARMACEUTICALS INC (ACHN) Delisted 10%+ Owner 10,816,953 — — -$20.72M 7 2013-12-31
ANADYS PHARMACEUTICALS INC (ANDS) Delisted 10%+ Owner 5,517,854 — — -$38.08M 9 2011-10-24
INHIBITEX, INC. (INHX) Delisted 10%+ Owner 7,900,662 — — -$457.9K 8 2011-09-28
MEDIVATION, INC. (MDVN) Delisted 10%+ Owner 13,567,136 — — -$9.15M 10 2011-06-09
TPC Group Inc. (TPCG) Delisted 10%+ Owner 2,705,145 — — -$5.40M 2 2011-01-04

Recent Filings

46 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-06-19 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +36,408 $302.8K EDGAR
2019-06-06 Myovant Sciences Ltd. (MYOV) Delisted Buy (P) +4,848,484 $40.00M EDGAR
2019-06-03 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +35,492 $277.9K EDGAR
2019-05-29 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +28,970 $220.9K EDGAR
2019-05-20 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +43,216 $325.8K EDGAR
2018-10-03 Urovant Sciences Ltd. (UROV) Delisted Buy (P) +5,357,142 $75.00M EDGAR
2018-06-07 — Buy (P) +28,571,428 $50.00M
2018-01-16 ABUS Buy (P) — $0 EDGAR
2017-10-17 ABUS Buy (P) — $0 EDGAR
2014-02-21 CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Mixed +1,119,998 $8.40M EDGAR
Showing 1–10 of 46
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.